AKR1B1 / Aldo-keto reductase family 1 member B1 · IHC design guide

Design Immunohistochemistry for AKR1B1

Plan AKR1B1 staining in paraffin sections using adrenal zona fasciculata cells as a strong positive reference (HPA tissue IHC). This guide covers fixation consistency, antigen retrieval, antibody incubation, chromogenic detection and cell-specific scoring.

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for AKR1B1 (IHC for AKR1B1): expected localisation Cytoplasmic expected (UniProt), antibody PB10035, validated IHC image, and IHC protocol steps — Printable **AKR1B1** IHC protocol sheet — expected localisation Cytoplasmic expected (UniProt), antibody PB10035, controls and protocol steps. Open the full AKR1B1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

AKR1B1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic expected (UniProt)
	Staining pattern	High in adrenal zona fasciculata cells; compartment unreported (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB10035)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet PB10035); verify before use.
	Caveat	Whole-adrenal scoring may mask zona fasciculata staining (HPA tissue IHC)
	Regulation	Osmotic stress in embryonic epithelia (UniProt)
	Isoform / epitope	No annotated isoforms; chain spans residues 2–316 (UniProt)

Section 1

Recommended AKR1B1 IHC & IF Protocols

The catalog antibody’s IHC protocol (datasheet PB10035) is followed by four published AKR1B1 paraffin IHC protocols (PMC8305663; PMC8217816; PMC8834204; PMC13346787).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded rat intestine tissues; fixative not specified (datasheet PB10035)
Fixation	Image fixative and duration unreported (datasheet PB10035); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB10035)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB10035)
Primary antibody	Rabbit anti-AKR1B1, 0.5-1μg/ml (datasheet PB10035)
Primary incubation	Overnight at 4 °C (datasheet PB10035)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB10035)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	AKR1B1-positive staining in cells in zona fasciculata of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Distinct expression in adrenal gland. No signal in the no-primary control.

💡Decision noteStart with heat retrieval in citrate at pH 6 (datasheet PB10035); the published workflows also report alkaline retrieval for human and pig tissues (PMC8305663; PMC8217816; PMC8834204).

Section 2

What Is the Expected AKR1B1 Staining Pattern?

AKR1B1 is a cytoplasmic protein without a transmembrane segment (UniProt P15121: location and topology). In paraffin-section IHC, expect strongest staining in adrenal zona fasciculata cells (HPA: High; tissue IHC reliability Enhanced). HPA also reports medium staining in selected cells of cerebellum, placenta, seminal vesicle, skin, and testis (HPA: tissue IHC). Judge both the stained cell type and its compartment.

What am I looking at on my slide?
Strong cytoplasmic staining in adrenal zona fasciculata cells.	This is the clearest expected positive pattern: HPA rates these cells High and reports Enhanced tissue IHC reliability (HPA: adrenal gland; tissue IHC). Compare intensity within the same run, since staining strength also depends on the assay (general IHC practice).
Moderate staining in Purkinje cells, cytotrophoblasts, seminal-vesicle glandular cells, basal-layer skin cells, or spermatogonia.	Each is a reported Medium-positive population (HPA: tissue IHC). HPA describes Purkinje-cell staining as cytoplasm/membrane; that observation should not be generalized into a transmembrane location for AKR1B1 (HPA: cerebellum; UniProt P15121: topology).
Staining confined to the cell surface, or a predominantly nuclear pattern without cytoplasmic signal.	Reassess specificity and slide quality: UniProt places AKR1B1 in the cytoplasm and reports no transmembrane segment (UniProt P15121: location and topology). HPA's additional nucleoplasmic signal comes from ICC-IF, so nuclear staining alone is not an established IHC tissue pattern (HPA: subcellular ICC-IF).
Prominent staining in an HPA-negative cell population, such as adipocytes or bronchial respiratory epithelium.	HPA reports AKR1B1 as Not detected in those specified cells (HPA: adipose tissue; bronchus). Check cell identification, antibody specificity, and detection controls; unexpected chromogen can also reflect endogenous detection activity (general IHC practice). An HPA negative is a comparator, not proof of universal absence.
Diffuse chromogen across cells and surrounding tissue, or no staining in adrenal zona fasciculata cells.	Diffuse staining lacks the reported cell-restricted pattern (HPA: tissue IHC) and suggests background requiring control review (general IHC practice). An unstained High-positive adrenal control makes the run inconclusive for negative test sections until staining and detection are checked (HPA: adrenal gland; general IHC practice).

💡Expected AKR1B1 appearanceCall a result positive when adrenal zona fasciculata cells show High, mainly cytoplasmic staining (HPA: adrenal gland; UniProt P15121: cytoplasm); widespread cell-independent chromogen is a background warning (general IHC practice).

How each factor affects the staining
Compartment and topology	AKR1B1 is cytoplasmic and has no transmembrane segment (UniProt P15121: location and topology). Assess cytoplasmic staining first; HPA's cytoplasm/membrane description is specific to cerebellar Purkinje cells in tissue IHC (HPA: cerebellum).
Choice of tissue control	Adrenal zona fasciculata cells provide the strongest supplied positive comparator (HPA: High). Adipocytes and bronchial respiratory epithelial cells are reported Not detected and can help assess unexpected staining in those specific populations (HPA: tissue IHC).
Strength of tissue-pattern evidence	HPA rates the tissue IHC profile Enhanced, citing consistency between antibody staining and RNA expression (HPA: tissue IHC). Four listed HPA antibodies carry Enhanced IHC status (HPA: antibody validation); this does not validate an unspecified catalog antibody or its dilution.
IF/ICC Q&A: Should the signal be exclusively cytosolic?	No. HPA reports mainly cytosolic signal with additional supported nucleoplasmic signal in ICC-IF (HPA: subcellular ICC-IF). That observation belongs to IF/ICC interpretation; it does not supply an IHC protocol or establish a predominantly nuclear tissue-IHC pattern.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Adrenal positive control has no signal.	The expected High-positive zona fasciculata population is absent from the result (HPA: adrenal gland); the failed step cannot be identified from staining alone (general IHC practice).	Confirm the zona fasciculata is present, then review antibody incubation, retrieval, detection reagents, and a working positive control (general IHC practice). Avoid scoring test sections negative until the control stains.
All tissue compartments show similar brown staining.	The cell-restricted HPA pattern is lost (HPA: tissue IHC); nonspecific binding or chromogenic background are possibilities (general IHC practice).	Review a no-primary control, blocking, washes, and detection conditions (general IHC practice). Compare the corrected run with the expected adrenal-cell distribution (HPA: adrenal gland).
HPA-negative adipocytes or bronchial epithelial cells stain strongly.	Those cell populations are reported Not detected (HPA: adipose tissue; bronchus). Cross-reactivity or endogenous detection activity is possible; morphology alone cannot distinguish them (general IHC practice).	Verify cell identity and examine no-primary and detection controls; compare with an adrenal positive control (general IHC practice; HPA: adrenal gland). Treat persistent unexpected staining cautiously.
Signal appears only at cell borders.	A border-only pattern conflicts with cytoplasmic localization and the absence of a transmembrane segment (UniProt P15121: location and topology), although HPA describes cytoplasm/membrane staining in Purkinje cells (HPA: cerebellum).	Check whether cytoplasm is also stained, review morphology and controls, and avoid generalizing the Purkinje-cell description to other tissues (HPA: cerebellum; general IHC practice).
Nuclei stain more strongly than cytoplasm.	HPA supports additional nucleoplasmic signal in ICC-IF, while UniProt lists cytoplasm and HPA gives no general nuclear tissue-IHC pattern (HPA: subcellular ICC-IF; UniProt P15121: location).	Evaluate a no-primary control and the cytoplasmic signal in the adrenal positive control before interpreting nuclear IHC staining as AKR1B1 (general IHC practice; HPA: adrenal gland).
A Medium-positive tissue is weak while the adrenal control stains.	The selected cell population is reported Medium, versus High in adrenal zona fasciculata cells (HPA: tissue IHC). This difference alone does not establish assay failure.	Identify the expected cells and compare runs under the same scoring criteria; investigate only if the tissue pattern or controls also disagree (HPA: tissue IHC; general IHC practice).

Source: UniProt P15121 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing AKR1B1 staining

IHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat intestine tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-AKR1B1 Antibody (PB10035) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB10035 · IHCIHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat intestine tissues. Heat

IHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat adrenal gland tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-AKR1B1 Antibody (PB10035) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB10035 · IHCIHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat adrenal gland tissues.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/cerebral+cortex#imid_20017553

HPA · Adrenal glandHuman Protein Atlas IHC, Adrenal gland. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/adrenal+gland#imid_247

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/colon#imid_20019479

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/liver#imid_20019480

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA026425; green = AKR1B1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for AKR1B1 IHC & IF

🧪Run adrenal gland first: cells in the zona fasciculata should stain (High; HPA positive row). Use adipose tissue as the negative comparison because adipocytes are Not detected (HPA negative row); on the adrenal slide, assess internal negative cells as adjacent cells without staining above local background, without assigning an unsupported cell identity (standard IHC practice).

Positive control tissue: Adrenal gland (Cells in zona fasciculata, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AKR1B1 in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).

Technical controls: Include a no-primary (secondary-only) control, a matched rabbit isotype control appropriate to the catalog antibody’s clonality, and AKR1B1 knockout material as a biological negative when available (PB10035 tissue-IHC caption: rabbit primary; standard IHC practice). Block endogenous peroxidase and check endogenous biotin background on the adrenal slide when using the caption’s biotinylated secondary, SABC and DAB detection (PB10035 tissue-IHC caption; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PB10035 rat-intestine paraffin-section caption does not report a fixative (PB10035 tissue-IHC caption). The caption used heat retrieval in citrate buffer at pH 6 for 20 minutes, but whether AKR1B1 staining depends on that retrieval is unreported (PB10035 tissue-IHC caption). Whether frozen sections or IF/ICC are easier is unreported; HPA shows ICC-IF images in A-431, U-251MG and U2OS with mainly cytosolic localisation, while no adrenal-specific artefact is identified in the supplied evidence (HPA subcellular; HPA positive row).

HPA tissue IHC evidence for AKR1B1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Cells in zona fasciculata	High	Protein (IHC)	HPA →
Cerebellum	Purkinje cells - cytoplasm/membrane	Medium	Protein (IHC)	HPA →
Placenta	Cytotrophoblasts	Medium	Protein (IHC)	HPA →
Seminal vesicle	Glandular cells	Medium	Protein (IHC)	HPA →
Skin	Cells in basal layer	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced AKR1B1 IHC Tips

Troubleshoot AKR1B1 staining in paraffin section IHC using the catalog antibody’s tissue image, protein localisation, and cell specific expression evidence.

How should I adjust retrieval if AKR1B1 staining is weak or uneven?

Start with heat mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet PB10035). The reported paraffin section image used that treatment before overnight incubation with 1 µg/mL primary antibody at 4°C (datasheet PB10035). If staining is weak, check deparaffinisation, heating consistency, and section attachment before changing retrieval conditions (standard IHC practice). Compare any revised retrieval condition with the documented citrate condition on adjacent sections, keeping detection and exposure to DAB constant (standard IHC practice). Use adrenal zona fasciculata cells as a reference for expected strong staining, while assessing morphology and background alongside intensity (HPA: High in zona fasciculata cells; standard IHC practice).

Could fixation explain weak AKR1B1 staining in my paraffin sections?

Target specific fixation sensitivity is unknown: the catalog antibody’s paraffin section caption does not state a fixative (datasheet PB10035). Record the fixative, time in fixative, tissue thickness, and processing schedule for each case before comparing staining across blocks (standard IHC practice). If weak staining tracks with processing, test adjacent sections under the documented pH 6, 20 minute citrate retrieval condition before changing several variables together (datasheet PB10035; standard IHC practice). Include a positive tissue reference in each run and check whether its cellular pattern remains interpretable (HPA: High in adrenal zona fasciculata cells; standard IHC practice). Do not assign a fixation mechanism from the observed staining pattern alone (standard IHC practice).

What cellular pattern should I expect, and how should I assess nuclear staining?

Expect predominantly cytoplasmic AKR1B1 staining, consistent with its annotated cytoplasmic location and supported cytosolic localisation (UniProt P15121 subcellular location; HPA subcellular). HPA also reports nucleoplasmic localisation in cell imaging, so limited nuclear signal merits comparison with matched controls rather than automatic rejection (HPA subcellular; standard IHC practice). AKR1B1 has no annotated transmembrane segment or signal peptide, making an exclusively sharp membrane outline an atypical pattern to investigate (UniProt P15121 topology and processing). In tissue, compare cellular staining with morphology: HPA reports high signal in adrenal zona fasciculata cells and medium signal in cerebellar Purkinje cells (HPA tissue IHC). Assess cytoplasmic and nuclear compartments separately when scoring (standard IHC practice).

How can I investigate staining that may reflect epitope masking or cross reactivity?

The supplied record lists no AKR1B1 isoforms, so divergent staining cannot be assigned to a documented alternative isoform here (UniProt P15121 isoforms). It annotates an N terminal processed chain beginning at residue 2 and modified residues at 2, 3, 95, 222, and 263 (UniProt P15121 processing and modified residues). Without a stated antibody epitope, those annotations cannot establish which modification affects recognition (datasheet PB10035: epitope unspecified; standard IHC interpretation). Compare serial sections under identical retrieval and detection settings, and seek independent antibody or orthogonal evidence if a pattern remains unexpected (standard IHC practice). Document whether the unexpected signal occurs in the expected cytoplasmic compartment and cell population (UniProt P15121 subcellular location; HPA tissue IHC).

How should I assess AKR1B1 in a multiplex IF experiment?

Treat IF as a separate application and validate antibody performance in that format before interpreting multiplex images (standard IF practice). Pair AKR1B1 with an independently validated marker for the expected cell population, such as a marker identifying adrenal zona fasciculata cells, and assess co localisation at single cell resolution (HPA: High in zona fasciculata cells; standard IF practice). Select fluorophores after checking unstained tissue for autofluorescence, and include single stain controls to assess channel bleed through (standard IF practice). Use permeabilisation appropriate for an intracellular epitope, since AKR1B1 is cytoplasmic and lacks a transmembrane segment (UniProt P15121 subcellular location and topology; standard IF practice). Compare any nuclear signal against the reported additional nucleoplasmic localisation and negative controls (HPA subcellular; standard IF practice).

What should I check when DAB appears outside expected AKR1B1 positive cells?

First inspect a no primary control to distinguish primary dependent signal from detection background (standard IHC practice). The catalog image used a biotinylated secondary antibody, a streptavidin–biotin complex, and DAB; evaluate background from that detection sequence in the tissue being tested (datasheet PB10035; standard IHC practice). Include a peroxidase block and assess endogenous peroxidase activity before attributing diffuse brown colour to AKR1B1 (standard chromogenic IHC practice). Titrate the primary antibody around the documented 1 µg/mL condition while holding retrieval and DAB development constant (datasheet PB10035; standard IHC practice). Compare suspect staining with adipocytes, reported as not detected, and with a positive tissue reference (HPA tissue IHC; standard IHC practice).

How should I score AKR1B1 across sections with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring, because AKR1B1 is primarily cytoplasmic and expression differs by tissue cell type (UniProt P15121 subcellular location; HPA tissue IHC). For intensity based comparisons, report an H score from the percentage of cells at each intensity category; also report the percentage of positive cells (standard IHC practice). If counting positive cells, express density per mm² of viable tissue or the defined compartment and report the area examined (standard IHC practice). Normalise comparisons to the same eligible cell population and staining run, using a shared positive reference to monitor run variation (standard IHC practice). Keep acquisition and scoring thresholds fixed across groups and exclude damaged tissue by prespecified rules (standard IHC practice).

How do I distinguish credible AKR1B1 staining from tissue and detection artefacts?

A credible result has interpretable cellular morphology and mainly cytoplasmic signal in a plausible cell population (UniProt P15121 subcellular location; HPA tissue IHC; standard IHC practice). High staining in adrenal zona fasciculata cells provides a useful positive reference, while HPA reports adipocytes as not detected (HPA tissue IHC). Investigate signal confined to section edges or necrotic areas, an exclusively membrane outlined pattern, and staining that also appears without primary antibody (UniProt P15121 topology; standard IHC practice). With DAB detection, check endogenous peroxidase and the biotin based detection sequence before calling diffuse brown deposits target positive (datasheet PB10035; standard IHC practice). Interpret intensity only after reviewing controls, compartment, and the identity of stained cells together (standard IHC practice).

Boster reagents

Best AKR1B1 / Aldo-keto reductase family 1 member B1 IHC Antibodies

PB10035 has IHC images of paraffin sections from rat intestine, rat adrenal gland, and human placenta (catalog IHC captions); no IF/ICC data are supplied (catalog applications and image inventory).

Real IHC data

Anti-AKR1B1 Antibody ®

Cat # PB10035

View product →

PB10035 is listed for IHC and has paraffin-section images from rat intestine, rat adrenal gland, and human placenta (catalog applications; catalog IHC captions). Its listed reactivity is human, mouse, and rat, while the supplied IHC images show human and rat samples (catalog reactivity; catalog IHC captions).

Which to pick: Choose PB10035 for paraffin-section IHC; its captions document citrate retrieval at pH 6 and 1 μg/ml primary antibody (PB10035 IHC captions). No IF/ICC application or image is supplied, so this payload does not support an IF/ICC recommendation (PB10035 catalog applications and image inventory). PB10035 lists human, mouse, and rat reactivity, but the supplied IHC images cover human and rat only; the fixative is unreported (PB10035 catalog reactivity; PB10035 IHC captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P15121 (ALDR_HUMAN, Aldo-keto reductase family 1 member B1).
Human Protein Atlas. AKR1B1 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. AKR1B1 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the nucleoplasm..
Human Protein Atlas. AKR1B1 antibody validation summary (4 antibodies).
AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers 2021 — PMC8305663.
Aldose Reductase B1 in Pig Seminal Plasma: Identification, Localization in Reproductive Tissues, and Relationship With Quality and Sperm Preservation. Frontiers in cell and developmental biology 2021 — PMC8217816.
AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Cancers 2022 — PMC8834204.
AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker. Scientific reports 2026 — PMC13346787.
PubMed PMID:2498333 — UniProt-cited evidence.
PubMed PMID:2504709 — UniProt-cited evidence.
PubMed PMID:2510130 — UniProt-cited evidence.